213 related articles for article (PubMed ID: 29062039)
1. A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit.
Kopinja J; Sevilla RS; Levitan D; Dai D; Vanko A; Spooner E; Ware C; Forget R; Hu K; Kral A; Spacciapoli P; Kennan R; Jayaraman L; Pucci V; Perera S; Zhang W; Fischer C; Lam MH
Sci Rep; 2017 Oct; 7(1):13853. PubMed ID: 29062039
[TBL] [Abstract][Full Text] [Related]
2. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Rohle D; Popovici-Muller J; Palaskas N; Turcan S; Grommes C; Campos C; Tsoi J; Clark O; Oldrini B; Komisopoulou E; Kunii K; Pedraza A; Schalm S; Silverman L; Miller A; Wang F; Yang H; Chen Y; Kernytsky A; Rosenblum MK; Liu W; Biller SA; Su SM; Brennan CW; Chan TA; Graeber TG; Yen KE; Mellinghoff IK
Science; 2013 May; 340(6132):626-30. PubMed ID: 23558169
[TBL] [Abstract][Full Text] [Related]
3. A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.
Machida Y; Nakagawa M; Matsunaga H; Yamaguchi M; Ogawara Y; Shima Y; Yamagata K; Katsumoto T; Hattori A; Itoh M; Seki T; Nishiya Y; Nakamura K; Suzuki K; Imaoka T; Baba D; Suzuki M; Sampetrean O; Saya H; Ichimura K; Kitabayashi I
Mol Cancer Ther; 2020 Feb; 19(2):375-383. PubMed ID: 31727689
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.
Andronesi OC; Arrillaga-Romany IC; Ly KI; Bogner W; Ratai EM; Reitz K; Iafrate AJ; Dietrich J; Gerstner ER; Chi AS; Rosen BR; Wen PY; Cahill DP; Batchelor TT
Nat Commun; 2018 Apr; 9(1):1474. PubMed ID: 29662077
[TBL] [Abstract][Full Text] [Related]
5. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
Pusch S; Krausert S; Fischer V; Balss J; Ott M; Schrimpf D; Capper D; Sahm F; Eisel J; Beck AC; Jugold M; Eichwald V; Kaulfuss S; Panknin O; Rehwinkel H; Zimmermann K; Hillig RC; Guenther J; Toschi L; Neuhaus R; Haegebart A; Hess-Stumpp H; Bauser M; Wick W; Unterberg A; Herold-Mende C; Platten M; von Deimling A
Acta Neuropathol; 2017 Apr; 133(4):629-644. PubMed ID: 28124097
[TBL] [Abstract][Full Text] [Related]
6. The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.
Natsume A; Arakawa Y; Narita Y; Sugiyama K; Hata N; Muragaki Y; Shinojima N; Kumabe T; Saito R; Motomura K; Mineharu Y; Miyakita Y; Yamasaki F; Matsushita Y; Ichimura K; Ito K; Tachibana M; Kakurai Y; Okamoto N; Asahi T; Nishijima S; Yamaguchi T; Tsubouchi H; Nakamura H; Nishikawa R
Neuro Oncol; 2023 Feb; 25(2):326-336. PubMed ID: 35722822
[TBL] [Abstract][Full Text] [Related]
7. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.
Tateishi K; Wakimoto H; Iafrate AJ; Tanaka S; Loebel F; Lelic N; Wiederschain D; Bedel O; Deng G; Zhang B; He T; Shi X; Gerszten RE; Zhang Y; Yeh JJ; Curry WT; Zhao D; Sundaram S; Nigim F; Koerner MVA; Ho Q; Fisher DE; Roider EM; Kemeny LV; Samuels Y; Flaherty KT; Batchelor TT; Chi AS; Cahill DP
Cancer Cell; 2015 Dec; 28(6):773-784. PubMed ID: 26678339
[TBL] [Abstract][Full Text] [Related]
8. Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration.
Cao H; Zhu G; Sun L; Chen G; Ma X; Luo X; Zhu J
Eur J Med Chem; 2019 Dec; 183():111694. PubMed ID: 31561044
[TBL] [Abstract][Full Text] [Related]
9. An in vivo patient-derived model of endogenous IDH1-mutant glioma.
Luchman HA; Stechishin OD; Dang NH; Blough MD; Chesnelong C; Kelly JJ; Nguyen SA; Chan JA; Weljie AM; Cairncross JG; Weiss S
Neuro Oncol; 2012 Feb; 14(2):184-91. PubMed ID: 22166263
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
Liu Z; Yao Y; Kogiso M; Zheng B; Deng L; Qiu JJ; Dong S; Lv H; Gallo JM; Li XN; Song Y
J Med Chem; 2014 Oct; 57(20):8307-18. PubMed ID: 25271760
[TBL] [Abstract][Full Text] [Related]
11. Friend or foe-IDH1 mutations in glioma 10 years on.
Huang LE
Carcinogenesis; 2019 Nov; 40(11):1299-1307. PubMed ID: 31504231
[TBL] [Abstract][Full Text] [Related]
12. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
[TBL] [Abstract][Full Text] [Related]
13. Metabolism, gliomas, and IDH1.
Smeitink J
N Engl J Med; 2010 Mar; 362(12):1144-5. PubMed ID: 20335593
[No Abstract] [Full Text] [Related]
14. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
[TBL] [Abstract][Full Text] [Related]
16. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.
Lazovic J; Soto H; Piccioni D; Lou JR; Li S; Mirsadraei L; Yong W; Prins R; Liau LM; Ellingson BM; Cloughesy TF; Lai A; Pope WB
Neuro Oncol; 2012 Dec; 14(12):1465-72. PubMed ID: 23090985
[TBL] [Abstract][Full Text] [Related]
17. Mutant IDH1 and thrombosis in gliomas.
Unruh D; Schwarze SR; Khoury L; Thomas C; Wu M; Chen L; Chen R; Liu Y; Schwartz MA; Amidei C; Kumthekar P; Benjamin CG; Song K; Dawson C; Rispoli JM; Fatterpekar G; Golfinos JG; Kondziolka D; Karajannis M; Pacione D; Zagzag D; McIntyre T; Snuderl M; Horbinski C
Acta Neuropathol; 2016 Dec; 132(6):917-930. PubMed ID: 27664011
[TBL] [Abstract][Full Text] [Related]
18. Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma.
Chen R; Nishimura MC; Kharbanda S; Peale F; Deng Y; Daemen A; Forrest WF; Kwong M; Hedehus M; Hatzivassiliou G; Friedman LS; Phillips HS
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14217-22. PubMed ID: 25225364
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of a novel mutant isocitrate dehydrogenase 1 inhibitor for glioma treatment.
Zhang N; Zheng B; Yao X; Huang X; Du J; Shen Y; Huang Z; Chen J; Lin Q; Lan W; Lin W; Ma W
Biochem Biophys Res Commun; 2021 Apr; 551():38-45. PubMed ID: 33714758
[TBL] [Abstract][Full Text] [Related]
20. Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.
Johannessen TA; Mukherjee J; Viswanath P; Ohba S; Ronen SM; Bjerkvig R; Pieper RO
Mol Cancer Res; 2016 Oct; 14(10):976-983. PubMed ID: 27430238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]